Publication of Clinical Study Shows Positive Benefits of KYAN’s Clinical Decision Support Platform for Cancer Patients

In largest potential examine so far of guided remedy for relapsed/refractory non-Hodgkin lymphoma sufferers, 59% had improved PFS over their earlier therapy

SINGAPORE, October 19, 2022 /EINPresswire.com/ — KYAN Therapeutics, a biotech firm with novel personalised medication and drug-dose mixture optimization know-how, introduced at present that its experimental-analytic hybrid platform which mixes ex vivo drug sensitivity of affected person samples and small knowledge AI, was utilized in a medical examine to instantly predict prime therapies that had been efficient for sufferers with relapsed/refractory non-Hodgkin lymphoma (RR-NHL). The findings of the examine had been revealed in AAAS’ peer-reviewed journal, Science Translational Medicine, with the publication title: “An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma.”

This potential cohort examine evaluated the feasibility of the computational drug mixture optimization platform, referred to within the examine as Quadratic Phenotypic Optimization Platform (QPOP), in medical choice help for sufferers who had acquired two or extra earlier traces of therapy. Unlike most prior research and different present approaches which use single-drug sensitivity assays and don’t tackle patient-specific drug mixture interactions, QPOP was capable of rank all potential drug combos from a single experimental check array and determine efficacious drug combos for RR-NHL sufferers.

75 affected person biopsies had been collected from 71 enrolled sufferers and 67/75 (89%) instances had been evaluated with a median turnaround time for outcomes of 6 days. The median follow-up for these sufferers was 24.5 months. Treating physicians selected from prime QPOP-ranked regimens and of the 17 sufferers handled in time for the cut-off evaluation of December 2021, 59% had improved development free survival (PFS) in comparison with their final line of therapy. One responder had a PFS of 23.6 months, representing an 8.9-fold enchancment, and one other distinctive responder achieved a 22.2-fold enchancment in PFS.

Dr. Masturah Rashid, Head of Research and Development at KYAN Therapeutics mentioned, “This is the only published prospective and interventional clinical study ever of an ex vivo drug combination platform and it highlights superior response and survival rates over standard of care therapies. QPOP-guided treatment was shown to significantly increase the average PFS by approximately three times juxtaposed with clinician-guided treatment. Utilizing patient-specific phenotypic response upon drug treatment uncovers more conclusive therapeutic options for these patients, as compared to using sequencing or biomarkers to dictate the next line of treatment.”

“KYAN’s focus on unlocking combination therapies which have long been a cornerstone of cancer treatment poises us to improve drug development, from target prioritization to patient stratification,” mentioned Hugo Saavedra, Chief Executive Officer of KYAN Therapeutics. “With the results of this study, we are now on the path to individualizing cancer treatment in a meaningful way where patients are not excluded due to lack of biomarkers or eligibility for clinical trials. Our goal is to give clinicians direct and useful data that allows for better patient outcomes and this study exhibits the ability of our platform to do that.”

About KYAN

KYAN Therapeutics is a biotechnology firm on a mission to bridge the most cancers care hole by advancing revolutionary applied sciences. Our know-how platforms had been developed in collaboration with UCLA and the National University of Singapore, combining small knowledge AI and organic experiments to redefine how therapies are developed and supplied to sufferers. From drug growth to personalised medication, KYAN presents an environment friendly resolution to determine the optimum end result to hundreds of thousands of doable drug-dose combos. KYAN’s know-how has been peer reviewed in a number of respected and excessive affect issue journals and applied in a number of medical research.

For extra particulars, please go to https://www.kyantherapeutics.com

Media Contact:
Lisa Chow
e-mail us right here
Visit us on social media:
LinkedIn